TriLink’s CleanCap technology produces optimal 5′ cap structures with over 95% efficiency, creating a co-transcriptional capping solution that dramatically improves mRNA yield and process time ...

According to the terms of the agreement, TriLink ® will supply its patented CleanCap ® M6, CleanCap ® AG 3’OMe, CleanCap ® AG, and CleanCap ® AU cap analogs for use in Lonza’s global mRNA ...

SAN DIEGO--(BUSINESS WIRE)-- TriLink BioTechnologies (TriLink ... the production of mRNAs containing the major natural cap structures found in humans, a significant improvement over legacy ...

TriLink BioTechnologies ® (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI), is fueling the future of mRNA research — starting with a significant donation to top academic labs across ...

SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- TriLink BioTechnologies (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has ...

TriLink BioTechnologies, a provider of life science reagents and services, has signed a non-exclusive License and Supply ...

Enabling the future development of critical therapeutics, Aldevron customers now have access to TriLink’s CleanCap mRNA capping technology for non-commercial use SAN DIEGO, February 04, 2025 ...

Agreement supports future expansion of essential therapeutics & vaccines in developing countries & regions TriLink’s CleanCap technology produces optimal 5′ cap structures with over 95% ...

TriLink BioTechnologies & Quantoom Biosciences ink license and supply pact for CleanCap mRNA capping technology: San Diego Wednesday, June 4, 2025, 16:00 Hrs [IST] TriLink BioTech ...